Track the Castle Biosciences, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €1bn. The latest transaction was disclosed on 25 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Derek Maetzold. All data is free.
7
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Castle Biosciences, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$44.00.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 19,563 of 29,063 companies
40.4
score / 100
Value
40
Quality
41
FCF yld2.8%
Earn yld-2.4%
EV/EBITDA·
ROE-4.2%
Gross mgn79%
Net mgn-7.0%
Debt/EBITDA3.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
23,844 shares@ US$24.71100.0% of flowCommonSEC144:0001958244-26-000421
7 of 7 declarations
Acerca de Castle Biosciences, Inc.
Castle Biosciences, Inc. es una empresa centrada en el desarrollo de pruebas de diagnóstico para el cáncer, con el objetivo de mejorar los resultados de los pacientes. Se especializa en soluciones basadas en genómica y biología molecular.